Your browser doesn't support javascript.
loading
Clinical characteristics of SARS-CoV-2-associated encephalopathy in children: Nationwide epidemiological study.
Kasai, Mariko; Sakuma, Hiroshi; Abe, Yuichi; Kuki, Ichiro; Maegaki, Yoshihiro; Murayama, Kei; Murofushi, Yuka; Nagase, Hiroaki; Nishiyama, Masahiro; Okumura, Akihisa; Sakai, Yasunari; Tada, Hiroko; Mizuguchi, Masashi; Takanashi, Jun-Ichi.
Afiliação
  • Kasai M; Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, Japan. Electronic address: kasai-mr@igakuken.or.jp.
  • Sakuma H; Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, Japan. Electronic address: sakuma-hs@igakuken.or.jp.
  • Abe Y; Division of Neurology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, Japan. Electronic address: abe-yu@ncchd.go.jp.
  • Kuki I; Department of Pediatric Neurology, Osaka City General Hospital, 2-13-22 Miyakojima-hondori, Miyakojima-ku, Osaka, Japan. Electronic address: i-kuki@med.osakacity-hp.or.jp.
  • Maegaki Y; Division of Child Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago-shi, Tottori, Japan. Electronic address: maegaki@med.tottori-u.ac.jp.
  • Murayama K; Center for Medical Genetics, Department of Metabolism, Chiba Children's Hospital, 579-1 Heta-cho, Midori-ku, Chiba-shi, Chiba, Japan.. Electronic address: kmuraya@mri.biglobe.ne.jp.
  • Murofushi Y; Department of Pediatrics and Pediatric Neurology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owada Shinden, Yachiyo-shi, Chiba, Japan. Electronic address: murofushi.yuka@twmu.ac.jp.
  • Nagase H; Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, Japan. Electronic address: nagase@med.kobe-u.ac.jp.
  • Nishiyama M; Department of Neurology, Hyogo Prefectural Kobe Children's Hospital, 1-6-7, Minatojima-minamimachi, Chuo-ku, Kobe-shi, Hyogo, Japan.
  • Okumura A; Department of Pediatrics, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute, Aichi, Japan. Electronic address: okumura.akihisa.479@mail.aichi-med-u.ac.jp.
  • Sakai Y; Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, Japan.
  • Tada H; Division of Pediatrics, Chibaken Saiseikai Narashino Hospital, 2-1-1 Miyama, Narashino-shi, Chiba, Japan.
  • Mizuguchi M; Department of Pediatrics, National Rehabilitation Center for Children with Disabilities, 1-1-10 Komone, Itabashi-ku, Tokyo, Japan. Electronic address: bradev@m.u-tokyo.ac.jp.
  • Takanashi JI; Department of Pediatrics and Pediatric Neurology, Tokyo Women's Medical University Yachiyo Medical Center, 477-96 Owada Shinden, Yachiyo-shi, Chiba, Japan. Electronic address: jtaka@twmu.ac.jp.
J Neurol Sci ; 457: 122867, 2024 Feb 15.
Article em En | MEDLINE | ID: mdl-38199023
ABSTRACT

OBJECTIVE:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sometimes triggers acute encephalopathy as a serious neurological complication in children. We previously reported the clinico-radiological findings of SARS-CoV-2-associated encephalopathy. The advent of the SARS-CoV-2 omicron variant led to a marked increase in pediatric patients with coronavirus disease 2019 (COVID-19); however, epidemiological changes with acute encephalopathy according to the emergence of SARS-CoV-2 have not yet been documented. Therefore, the present study investigated epidemiological differences in SARS-CoV-2-associated encephalopathy during the BA.1/BA.2 and BA.5 predominant periods and also between SARS-CoV-2-associated and non-SARS-CoV-2-associated encephalopathy.

METHODS:

We conducted a nationwide survey of SARS-CoV-2-associated encephalopathy in Japanese children between June and November 2022. We compared the present results during the BA.5 predominant period and previous findings during the BA.1/BA.2 predominant period. We also compared the clinico-radiological syndromes of encephalopathy between SARS-CoV-2-associated and non-SARS-CoV-2-associated encephalopathy.

RESULTS:

Although many patients with SARS-CoV-2-associated encephalopathy in the BA.5 predominant period had seizures as their initial symptoms, no significant differences were observed in the clinical features. Patients with SARS-CoV-2-associated encephalopathy had worse outcomes than those with non-SARS-CoV-2-associated encephalopathy (p-value = 0.003). Among 103 patients with SARS-CoV-2-associated encephalopathy, 14 (13.6%) had severe types of acute encephalopathy, namely, encephalopathy with acute fulminant cerebral edema (AFCE) and hemorrhagic shock and encephalopathy syndrome (HSES). Also, 28 (27.2%) patients with SARS-CoV-2-associated encephalopathy had poor

outcome:

severe neurological sequelae or death. Ninety-five patients (92.2%) were not vaccinated against SARS-CoV-2.

CONCLUSIONS:

In SARS-CoV-2-associated encephalopathy, high percentages of AFCE and HSES can result in poor outcomes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Hemorrágico / Transtornos da Coagulação Sanguínea / Encefalopatias / COVID-19 Tipo de estudo: Risk_factors_studies Limite: Child / Humans Idioma: En Revista: J Neurol Sci Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Choque Hemorrágico / Transtornos da Coagulação Sanguínea / Encefalopatias / COVID-19 Tipo de estudo: Risk_factors_studies Limite: Child / Humans Idioma: En Revista: J Neurol Sci Ano de publicação: 2024 Tipo de documento: Article
...